04:02 PM EST - Antibe Therapeutics Inc. : Announced that its lead drug, ATB-346, met the primary endpoint in the Phase 2B dose-ranging, efficacy study. Both the 250 mg and 200 mg doses of ATB-346 demonstrated superiority to placebo in reducing osteoarthritis pain with a high level of statistical significance. Antibe Therapeutics Inc.
shares V.ATE are trading down $0.17 at $0.60.
